Keywords: Sandoz, Rituximab, Novartis, Roche, Biosimilar, Rituxan, MabThera

Sandoz moves forward with development of biosimilar rituximab, Roche’s blockbuster RA drug

Article | 11 January 2011

Print This

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX) Sandoz says that it has begun a Phase II ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in